Obesity Devices For Children Should Be Tested In Sickest First – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Children initially enrolled in trials for devices that treat obesity should have a serious co-morbidity, concurred several panel members of FDA's Pediatric Advisory Committee
You may also be interested in...
Medtronic Launches Obesity Division With $260 Mil. Transneuronix Purchase
Transneuronix' Transcend gastric electrical stimulation device is the first product scheduled for commercialization by Medtronic's obesity management division
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.